Protagen Shifting to Focus on Cancer Immunotherapy – GenomeWeb
|
Protagen Shifting to Focus on Cancer Immunotherapy
GenomeWeb NEW YORK (GenomeWeb) – With a series of recent collaborations, German biomarker firm Protagen is shifting its focus to cancer immunotherapy. Over the last year the company has signed agreements with the German National Center for Tumor Diseases, the … |
